Globus Medical Class A (GMED) closed at $81.83 on October 26, 2026, up 0.5% from the previous close, on volume of 973,554 shares (30-day average 1,474,786).
Data as of October 26, 2026.
Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm
PRNewswire (Wed, 21-Oct 4:26 PM ET)
Globe Newswire (Wed, 14-Oct 8:00 AM ET)
Globus Medical Schedules Third Quarter Earnings Release and Conference Call
Globe Newswire (Mon, 12-Oct 4:01 PM ET)
Globus Medical Announces CE Mark for Excelsius3D Imaging System
Globe Newswire (Thu, 3-Sep 4:30 PM ET)
Globe Newswire (Wed, 26-Aug 5:57 PM ET)
Globus Medical Reports Second Quarter 2026 Results
Globe Newswire (Thu, 6-Aug 4:15 PM ET)
Globus Medical Expects Record 2025 Revenue, Raises 2026 Guidance Following Strong Q4 Results
Market Chameleon (Thu, 8-Jan 6:58 AM ET)
Market Chameleon (Fri, 7-Nov 5:29 AM ET)
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
Globus Medical Class A trades on the NYSE stock market under the symbol GMED.
As of October 26, 2026, GMED stock price climbed to $81.83 with 973,554 million shares trading.
GMED has a beta of -0.00, meaning it tends to be less sensitive to market movements. GMED has a correlation of 0.00 to the broad based SPY ETF.
GMED has a market cap of $10.99 billion. This is considered a Large Cap stock.
Last quarter Globus Medical Class A reported $790 million in Revenue and $1.34 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.24.
In the last 3 years, GMED traded as high as $101.40 and as low as $43.39.
The top ETF exchange traded funds that GMED belongs to (by Net Assets): IJH, VTI, VB, VBK, VXF.
GMED has outperformed the market in the last year with a price return of +30.3% while the SPY ETF gained +15.1%. GMED has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +8.5% and +9.6%, respectively, while the SPY returned +3.9% and -1.7%, respectively.
GMED support price is $79.82 and resistance is $83.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GMED shares will trade within this expected range on the day.
